- Home
- NTRB vs NTHI Comparison
NTRB vs NTHI Comparison
Compare NTRB & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- NTHI
- Stock Information
- Founded
- NTRB 2016
- NTHI 2008
- Country
- NTRB United States
- NTHI United States
- Employees
- NTRB N/A
- NTHI N/A
- Industry
- NTRB Industrial Specialties
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- NTHI Health Care
- Exchange
- NTRB Nasdaq
- NTHI Nasdaq
- Market Cap
- NTRB 94.3M
- NTHI 110.9M
- IPO Year
- NTRB N/A
- NTHI N/A
- Fundamental
- Price
- NTRB $7.34
- NTHI $4.81
- Analyst Decision
- NTRB Buy
- NTHI
- Analyst Count
- NTRB 1
- NTHI 0
- Target Price
- NTRB $13.00
- NTHI N/A
- AVG Volume (30 Days)
- NTRB 172.5K
- NTHI 547.1K
- Earning Date
- NTRB 09-02-2025
- NTHI 01-01-0001
- Dividend Yield
- NTRB N/A
- NTHI N/A
- EPS Growth
- NTRB N/A
- NTHI N/A
- EPS
- NTRB N/A
- NTHI N/A
- Revenue
- NTRB $2,398,437.00
- NTHI $79,990.00
- Revenue This Year
- NTRB $560.75
- NTHI N/A
- Revenue Next Year
- NTRB $588.39
- NTHI N/A
- P/E Ratio
- NTRB N/A
- NTHI N/A
- Revenue Growth
- NTRB 18.92
- NTHI 13.52
- 52 Week Low
- NTRB $2.98
- NTHI $3.20
- 52 Week High
- NTRB $9.42
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- NTRB 37.59
- NTHI N/A
- Support Level
- NTRB $6.69
- NTHI N/A
- Resistance Level
- NTRB $9.21
- NTHI N/A
- Average True Range (ATR)
- NTRB 0.62
- NTHI 0.00
- MACD
- NTRB -0.20
- NTHI 0.00
- Stochastic Oscillator
- NTRB 8.34
- NTHI 0.00
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").